A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Larynx | Lip, Oral Cavity and Pharynx
What is the purpose of this trial?
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.
- Trial withCelldex Therapeutics Inc. (Subsidiary of Medarex, Inc.)
- Start Date12/01/2019
- End Date11/30/2019
- Last Updated12/04/2019
- Study HIC#2000023823